- Home
- ESLA vs LVTX Comparison
ESLA vs LVTX Comparison
Compare ESLA & LVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESLA
- LVTX
- Stock Information
- Founded
- ESLA 2021
- LVTX 2016
- Country
- ESLA United States
- LVTX Netherlands
- Employees
- ESLA N/A
- LVTX N/A
- Industry
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- LVTX Biotechnology: Pharmaceutical Preparations
- Sector
- ESLA Health Care
- LVTX Health Care
- Exchange
- ESLA Nasdaq
- LVTX Nasdaq
- Market Cap
- ESLA 35.9M
- LVTX 41.3M
- IPO Year
- ESLA N/A
- LVTX 2021
- Fundamental
- Price
- ESLA $1.05
- LVTX $1.54
- Analyst Decision
- ESLA Strong Buy
- LVTX Hold
- Analyst Count
- ESLA 1
- LVTX 4
- Target Price
- ESLA $16.00
- LVTX $1.58
- AVG Volume (30 Days)
- ESLA 25.2K
- LVTX 104.7K
- Earning Date
- ESLA 08-12-2025
- LVTX 08-13-2025
- Dividend Yield
- ESLA N/A
- LVTX N/A
- EPS Growth
- ESLA N/A
- LVTX N/A
- EPS
- ESLA N/A
- LVTX N/A
- Revenue
- ESLA N/A
- LVTX $4,990,000.00
- Revenue This Year
- ESLA N/A
- LVTX N/A
- Revenue Next Year
- ESLA N/A
- LVTX N/A
- P/E Ratio
- ESLA N/A
- LVTX N/A
- Revenue Growth
- ESLA N/A
- LVTX N/A
- 52 Week Low
- ESLA $0.63
- LVTX $0.85
- 52 Week High
- ESLA $1.78
- LVTX $2.09
- Technical
- Relative Strength Index (RSI)
- ESLA 61.31
- LVTX 52.16
- Support Level
- ESLA $0.99
- LVTX $1.53
- Resistance Level
- ESLA $1.08
- LVTX $1.58
- Average True Range (ATR)
- ESLA 0.07
- LVTX 0.03
- MACD
- ESLA 0.00
- LVTX -0.01
- Stochastic Oscillator
- ESLA 76.63
- LVTX 41.67
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.